Quanterix Advances Alzheimer's Diagnostic to H2 FDA Review, Names New CFO
QTRX sits 34% above its 52-week low of $2.395.
Summary
Quanterix appointed Jason Faessler as its new CFO, effective June 22, 2026, following the previously announced departure of Vandana Sriram and the 8-K filing on June 9th. Crucially, the company is advancing a five-marker Alzheimer's diagnostic for expected FDA review in the second half of the year. This development is a significant step towards commercialization, supported by plans to boost commercial operations and R&D, with a target of achieving cash-flow breakeven by year-end.
At the time of this announcement, QTRX was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.6M. The 52-week trading range was $2.40 to $8.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.